ADVICENNE (ALDVI.PA) Stock Price, Quote, News and Overview
EPA:ALDVI - Euronext Paris - Matif - FR0013296746 - Common Stock - Currency: EUR
ALDVI.PA Quote, Performance and Key Statistics
EPA:ALDVI (5/9/2025, 7:00:00 PM)
1.764
+0.02 (+1.38%)
The current stock price of ALDVI.PA is 1.764 EUR. In the past month the price increased by 12.36%. In the past year, price decreased by -1.67%.
ALDVI.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 54.92 | 634.11B | ||
| 1LLY.MI | ELI LILLY & CO | 54.27 | 626.62B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.52 | 375.45B | ||
| JNJ.DE | JOHNSON & JOHNSON | 15.52 | 332.42B | ||
| NOV.DE | NOVO NORDISK A/S-B | 19.55 | 263.01B | ||
| RHO.DE | ROCHE HOLDING AG-BR | N/A | 244.88B | ||
| 1SAN.MI | SANOFI | 14.56 | 239.91B | ||
| SAN.PA | SANOFI | 13.81 | 227.47B | ||
| SNW.DE | SANOFI | 13.78 | 227.01B | ||
| 1MRKX.MI | MERCK & CO. INC. | 10.77 | 186.97B | ||
| 6MK.DE | MERCK & CO. INC. | 10 | 173.63B | ||
| PFE.DE | PFIZER INC | 7.03 | 113.29B |
Related stock screener links
About ALDVI.PA
Company Profile
Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
Company Info
ADVICENNE
262, Rue du Faubourg Saint Honore
Paris ILE-DE-FRANCE FR
Employees: 21
Phone: 33185733620
ADVICENNE / ALDVI.PA FAQ
What is the stock price of ADVICENNE today?
The current stock price of ALDVI.PA is 1.764 EUR. The price increased by 1.38% in the last trading session.
What is the ticker symbol for ADVICENNE stock?
The exchange symbol of ADVICENNE is ALDVI and it is listed on the Euronext Paris - Matif exchange.
On which exchange is ALDVI.PA stock listed?
ALDVI.PA stock is listed on the Euronext Paris - Matif exchange.
What is the price forecast or stock price prediction for ADVICENNE stock?
9 analysts have analysed ALDVI.PA and the average price target is 4.08 EUR. This implies a price increase of 131.29% is expected in the next year compared to the current price of 1.764. Check the ADVICENNE stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ADVICENNE worth?
ADVICENNE (ALDVI.PA) has a market capitalization of 21.73M EUR. This makes ALDVI.PA a Nano Cap stock.
How many employees does ADVICENNE have?
ADVICENNE (ALDVI.PA) currently has 21 employees.
What are the support and resistance levels for ADVICENNE (ALDVI.PA) stock?
ADVICENNE (ALDVI.PA) has a support level at 1.75 and a resistance level at 1.77. Check the full technical report for a detailed analysis of ALDVI.PA support and resistance levels.
Is ADVICENNE (ALDVI.PA) expected to grow?
The Revenue of ADVICENNE (ALDVI.PA) is expected to decline by -31.03% in the next year. Check the estimates tab for more information on the ALDVI.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ADVICENNE (ALDVI.PA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALDVI.PA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALDVI.PA, evaluating the profitability, health, valuation and growth aspects
- ADVICENNE (ALDVI.PA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ADVICENNE (ALDVI.PA) Sales and EPS estimates to see what analysts future expectations are.
- ADVICENNE (ALDVI.PA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ADVICENNE (ALDVI.PA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ADVICENNE (ALDVI.PA) Stock Chart to make your own analysis
- ADVICENNE (ALDVI.PA) Latest news and press-releases to stay up to date.
Does ADVICENNE (ALDVI.PA) stock pay dividends?
ALDVI.PA does not pay a dividend.
What is the Price/Earnings (PE) ratio of ADVICENNE (ALDVI.PA)?
ADVICENNE (ALDVI.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.67).
ALDVI.PA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ALDVI.PA. When comparing the yearly performance of all stocks, ALDVI.PA is a bad performer in the overall market: 75.97% of all stocks are doing better.
ALDVI.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALDVI.PA. Both the profitability and financial health of ALDVI.PA have multiple concerns.
ALDVI.PA Financial Highlights
Over the last trailing twelve months ALDVI.PA reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS increased by 40.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -88.23% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALDVI.PA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to ALDVI.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 8.77% and a revenue growth -31.03% for ALDVI.PA